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PPRECLINICAL STUDIES
A Relationship Between
Vascular Endothelial Growth Factor,
Angiogenesis, and Cardiac Repair After
Muscle Stem Cell Transplantation Into Ischemic Hearts
Thomas R. Payne, PHD,*‡§ Hideki Oshima, MD, PHD,*§ Masaho Okada, MD,*§
Nobuo Momoi, MD,† Kimimasa Tobita, MD,† Bradley B. Keller, MD,† Hairong Peng, MD, PHD,*§
Johnny Huard, PHD*‡§
Pittsburgh, Pennsylvania
Objectives We investigated whether vascular endothelial growth factor (VEGF) was associated with the angiogenic and ther-
apeutic effects induced after transplantation of skeletal muscle-derived stem cells (MDSCs) into a myocardial
infarction (MI).
Background Because very few MDSCs were found to differentiate into new blood vessels when injected into the heart, the
mechanism underlying the occurrence of angiogenesis after MDSC transplantation is currently unknown. In the
present study, we used a gain- or loss-of-VEGF function approach with skeletal MDSCs engineered to express
VEGF or soluble Flt1, a VEGF-specific antagonist, to identify the involvement of VEGF in MDSC transplantation-
induced neoangiogenesis.
Methods Vascular endothelial growth factor- and soluble Flt1-engineered MDSCs were injected into an acute MI. Angio-
genesis and cardiac function were evaluated by immunohistochemistry and echocardiography.
Results Both control and VEGF-overexpressing MDSCs induced angiogenesis, prevented adverse cardiac remodeling, and
improved function compared with saline-injected hearts. However, these therapeutic effects were diminished in
hearts transplanted with MDSCs expressing soluble Flt1 despite successful cell engraftment. In vitro experiments
demonstrated that MDSCs increased secretion of VEGF in response to hypoxia and cyclic stretch (likely condi-
tions in ischemic hearts), suggesting that transplanted MDSCs release VEGF in vivo.
Conclusions Our findings suggest that VEGF is essential for the induction of angiogenesis and functional improvements ob-
served after MDSC transplantation for infarct repair. (J Am Coll Cardiol 2007;50:1677–84) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.100a
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trogenitor cells of skeletal muscle have been considered
dvantageous for clinical use, since skeletal muscle is an
bundant and accessible tissue source, isolated cells are
ighly proliferative in culture, and transplantation can be
erformed in an autologous approach. However, limitations
rom the *Stem Cell Research Center and †Pediatric Cardiovascular Research
rogram, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania; and the
epartments of ‡Bioengineering, §Orthopaedic Surgery, and Molecular Genetics
nd Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania. This work was
upported, in part, by grants from the National Institutes of Health (1U54AR050733-01
to Dr. Huard], R01-HL 069368 [to Dr. Huard], R01HL65219-04), Muscular Dystro-
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ith support from Research Facilities Improvement Program Grant C06 RR-14489 from
he National Center for Research Resources, National Institutes of Health.(
Manuscript received January 5, 2007; revised manuscript received April 3, 2007,
ccepted April 22, 2007.ssociated with skeletal muscle-derived cells for cardiac
epair are based on reports showing inadequate differentia-
ion of transplanted cells into a cardiac phenotype and
imited electromechanical coupling and synchronous con-
raction with one another or with host myocardium via the
xpression of connexin-43 gap junction protein (1–7).
See page 1685
espite these deficiencies, myogenic cells still have demon-
trated therapeutic improvements of cardiac function in
arious experimental animal models (8). Although the exact
echanism for the beneficial effect of myoblast transplan-
ation is unknown, the inhibition of adverse remodeling and
he induction of neoangiogenesis appear to be major factors
9,10).
(
a
n
p
t
p
p
o
h
a
(
M
i
h
i
a
s
t
w
f
M
a
b
O
n
h
a
V
w
r
a
m
g
h
t
t
M
C
s
c
c
n
d
d
V
(
(
d
m
d
c
p
1
(
7
M
s
A
P
5
(
N
M
l
i
t
g
1
M
T
s
h
n
b
m
c
C
i
c
s
M
m
I
w
(
d
a
1678 Payne et al. JACC Vol. 50, No. 17, 2007
MDSC, VEGF, and Angiogenesis for Cardiac Repair October 23, 2007:1677–84We have previously shown
that mouse skeletal muscle-
derived stem cells (MDSCs) in-
jected into hearts after myocar-
dial infarction (MI) improve
cardiac function more effec-
tively than do committed skel-
etal myoblasts (1). Because only
a very low percentage of trans-
planted MDSCs expressed
connexin-43 gap junctions and
acquired a cardiomyocyte phe-
notype through either differen-
tiation or fusion with host car-
diomyocytes (1,5), we largely
attributed this functional advan-
tage to a greater ability of MDSCs
to survive, engraft, and induce
neoangiogenesis within the infarct
1). Furthermore, very few donor-derived MDSCs differenti-
te or fuse into blood-vessel-like structures, indicating that the
eovasculature resulting after MDSC transplantation is com-
rised mostly of host-derived cells (1,5). This led us to consider
he mechanism for neovascular induction after MDSC trans-
lantation into ischemic myocardium.
Recent evidence suggests that cardiac cell therapy
rovides therapeutic benefit through the paracrine actions
f factors released by transplanted cells (11). Indeed, we
ave previously demonstrated that one of the most potent
ngiogenic factors, vascular endothelial growth factor
VEGF), was expressed by many of our engrafted
DSCs between 1 and 12 weeks after transplantation
nto an MI. On the basis of these observations, we
ypothesized that VEGF could be a primary factor in the
schemic milieu that is responsible for the induction of
ngiogenesis within the infarct (1). We, therefore, de-
igned experiments to investigate the angiogenic and
herapeutic role of VEGF in infarcted hearts injected
ith MDSCs.
To test this, we performed gain- and loss-of-VEGF
unction experiments using genetically engineered mouse
DSCs that over-express VEGF or the VEGF-specific
ntagonist soluble Flt1 (sFlt1), to enhance or inhibit the
iological effects of VEGF within ischemic myocardium.
ur results demonstrate that VEGF stimulates, and is
ecessary for, angiogenesis in MDSC-transplanted
earts. Additionally, the therapeutic benefit observed,
fter MDSC transplantation, was diminished when
EGF-induced infarct neovascularization was inhibited
ith sFlt1. Finally, we demonstrated that MDSCs up-
egulate the secretion of VEGF when exposed to hypoxia
nd cyclic stretch (likely conditions within ischemic
yocardium), further supporting the notion that en-
rafted MDSCs release VEGF to the milieu of infarcted
Abbreviations
and Acronyms
FS  fractional shortening
fskMyHC  fast skeletal
myosin heavy chain
LV  left
ventricle/ventricular
MDSC  muscle-derived
stem cell
MI  myocardial infarction
nLacZ  nuclear-localized
LacZ
PBS  phosphate-buffered
saline
sFlt1  soluble Flt1
VEGF  vascular
endothelial growth factorearts. These results confirm that VEGF is necessary for phe therapeutic induction of angiogenesis after MDSC
ransplantation for MI repair.
ethods
ell culture and transduction to express VEGF and
Flt1. Mouse MDSCs were isolated and cultured, and
onstruction of the retroviral vectors containing genes en-
oding human VEGF 165, human sFlt1, or bacterial
uclear-localized LacZ (nLacZ) was performed as previously
escribed by members of our laboratory (12,13). Muscle-
erived stem cells were retrovirally transduced to express the
EGF transgene (MDSC-VEGF), the sFlt1 transgene
MDSC-FLT), and the nLacZ transgene (MDSC-LacZ)
12). Because the long-term overexpression of VEGF in-
uces deleterious side effects in vivo, including hemangio-
as (14–16), we avoided this problem by decreasing the
osage of VEGF released from transplanted MDSCs. We
ombined MDSC-VEGF cells with control MDSCs ex-
ressing nLacZ (MDSC-LacZ) at 2 different dilutions:
) 50% MDSC-VEGF cells and 50% MDSC-LacZ cells
MDSC-VEGF50); and 2) 25% MDSC-VEGF cells and
5% MDSC-LacZ cells (MDSC-VEGF25).
I and cell transplantation. All animal experiments and
urgical procedures were approved by the Institutional
nimal Care and Use Committee of Children’s Hospital of
ittsburgh (protocol no. 07/03). Acute MI was induced in
6 non-obese diabetic-severe combined immunodeficient
NOD-SCID) mice (male, age 16 weeks, 25 to 30 g,
OD.CB17-PrkdcSCID/J, Jackson Laboratory, Bar Harbor,
aine), as previously described (1). Immediately after
igation, 3  105 cells were transplanted directly into the
schemic region, as previously described (1). The investiga-
ors were blinded to the solution contents injected into each
roup of mice: phosphate-buffered saline (PBS) only (n 
1 mice), MDSC-LacZ (n  11), MDSC-FLT (n  12),
DSC-VEGF25 (n  11), or MDSC-VEGF50 (n  11).
issue processing, histological and immunohistochemical
tainings. Mice were euthanized, and their hearts were
arvested and frozen in 2-methylbutane precooled in liquid
itrogen, and serially cryosectioned (from the apex to the
ase) into 7 m-thick sections. A mouse antifast skeletal
yosin heavy chain (fskMyHC) antibody (1:400, MY-32
lone, Sigma, St. Louis, Missouri) and a rat antimouse
D31 antibody (1:100, BD Pharmingen, San Diego, Cal-
fornia) were used to immunostain skeletal myofibers and
apillaries as previously described (1,5,12). We used Mas-
on’s Modified IMEB Trichrome Stain Kit (IMEB, San
arcos, California) to stain the infarct scar according to the
anufacturer’s instructions.
mage analysis. All fluorescent and brightfield microscopy
as performed with a Nikon Eclipse E800 microscope
Nikon Corp., Tokyo, Japan) equipped with a Retiga EXi
igital camera (Q Imaging, Burnaby, Canada). Images were
cquired with Northern Eclipse software (version 6.0, Em-
ix Imaging, Inc., Cheektowaga, New York). Capillary
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October 23, 2007:1677–84 MDSC, VEGF, and Angiogenesis for Cardiac Repairensity, cell engraftment size, left ventricle (LV) scar tissue
rea ratio, and LV infarct size measurements were per-
ormed with ImageJ software (version 1.32j, National Insti-
utes of Health, Bethesda, Maryland). We measured
D31[] capillary density (CD31[] capillary structures
er high-power field [HPF]) within the infarct and fsk-
yHC[] area in the digital images of HPF (200
agnification) obtained from each group (n  3 hearts/
roup/time point at 2, 6, and 12 weeks after injection). To
easure LV infarct size and scar tissue area ratio, digital
mages of low-power fields (20) of the entire LV cross
ection were captured from the Masson’s trichrome-stained
earts. From these images, scar tissue area ratio was defined
s the ratio of LV fibrosis to the area of normal LV
yocardium, and LV infarct size was measured as the
ercentage of LV endocardial surface length infarcted to the
otal LV endocardial surface.
chocardiography. Echocardiograms assessed LV dimen-
ions and systolic function (blinded investigator; 2, 6, and 12
eeks after cell transplantation), as previously described (1).
wo-dimensional images were obtained at the midpapillary
uscle level. Left ventricular end-diastolic area (EDA) and
nd-systolic area (ESA) were measured from short-axis images
f the LV, and both LV end-diastolic dimension (EDD) and
nd-systolic dimension (ESD) were measured from at least 6
onsecutive beats via M-mode tracing. To measure LV con-
ractility, fractional shortening (FS) was calculated as FS (%)
(EDD  ESD)  EDD]  100, and fractional area change
FAC) was calculated as FAC (%)  [(EDA  ESA) 
DA]  100.
n vitro stimulation of MDSCs. Hypoxia was induced by
ulturing MDSCs in an incubator (Heraeus, Newtown,
onnecticut) for 24 h in proliferation medium (PM) (Dul-
ecco’s Modified Eagle’s Medium [DMEM], 10% FBS,
0% horse serum, 1% penicillin/streptomycin, and 0.5%
hicken embryo extract) or serum-free medium (DMEM)
t 37°C and 2.5% O2 (n  3 samples/group). Cyclic stretch
as applied with a Flexercell Strain Unit (Flexcell Interna-
ional, Export, Pennsylvania). Muscle-derived stem cells
ere cultured to high confluency on collagen type 1-coated
ioflex culture plates (Flexcell International) and subjected
o a 10% average surface elongation at 30 cycles/min for 1,
, 10, and 24 h (n  3 samples/group/time point). After
ach assay, the cell culture supernatant was collected and
nalyzed for VEGF by enzyme-linked immunoadsorbent
ssay (R&D Systems, Minneapolis, Minnesota). Cells were
lso collected and counted with a hemacytometer.
tatistical analysis. All measured data are presented as
ean  standard error. Statistical differences were deter-
ined by 2-way analysis of variance. When statistical
ifferences were observed, the Student-Newman-Keuls
ultiple comparison test was used to perform post-hoc
nalysis (Sigma Stat, version 2.0, Jandel Scientific, San
afael, California). Vesults
nfarct neovascularization. The injection of MDSC-LacZ
ells induced greater neovascularization of the infarct than
id the injection of PBS (p  0.01) (Fig. 1); however, we
bserved less angiogenesis in the MDSC-LacZ group than
n both the MDSC-VEGF25 and MDSC-VEGF50
roups at all time points (p  0.01) (Fig. 1). The MDSC-
EGF25 and MDSC-VEGF50 groups displayed the
reatest capillary density at all time points when compared
ith the other groups (p  0.01) (Fig. 1). Despite the
xpected secretion of considerably more VEGF in the
DSC-VEGF50 group than in the MDSC-VEGF25
roup, the MDSC-VEGF50-injected hearts displayed sim-
lar capillary density to MDSC-VEGF25-injected hearts at
ll tested time points (Fig. 1). Antagonism of VEGF with
Flt1 in the MDSC-FLT group resulted in levels of infarct
ascularization comparable to the PBS group and consider-
bly less than the MDSC-LacZ group at all tested time
oints (p  0.01) (Fig. 1). Taken together, these results
uggest that VEGF alone stimulated more angiogenesis
hen overexpressed, and that antagonism of VEGF with
Flt1 inhibited the angiogenesis associated with MDSC
ransplantation.
berrant angiogenesis. Prior research shows that VEGF
verexpression may result in abnormal vasculature at high
icro-environmental dosages (14–17). Despite our efforts
o control the amount of VEGF delivered by the VEGF-
ngineered MDSCs, hearts injected with the MDSC-
Figure 1 VEGF-Induced Infarct Neovascularization
Hearts in the muscle-derived stem cell (MDSC)-LacZ, MDSC-vascular endothe-
lial growth factor (VEGF)25, and MDSC-VEGF50 groups contained the most
blood vessels per high-power field (HPF) (200 magnification) in the infarct
area, and significantly more than the phosphate-buffered saline (PBS)- or
MDSC-FLT–injected hearts (*p  0.01 vs. PBS; †p  0.01 vs. MDSC-FLT).
Hearts in the MDSC-FLT group displayed comparable vascularity to the control
PBS-injected hearts. The MDSC-VEGF25 and MDSC-VEGF50 groups displayed
higher capillary densities than the MDSC-LacZ group (‡p  0.01 vs. MDSC-
LacZ). The MDSC-VEGF25 group displayed comparable vascularity to the
MDSC-VEGF50 group.EGF50 group developed disorganized vascular structures
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MDSC, VEGF, and Angiogenesis for Cardiac Repair October 23, 2007:1677–842 weeks after MI (Fig. 2). However, hearts in the MDSC-
EGF25 and MDSC-LacZ groups exhibited normal mor-
hology and spatial organization of blood vessels within the
I at all tested time points (Fig. 2).
onor cell engraftment. Previously, we have shown that
he vast majority of MDSCs transplanted into the heart
ifferentiate into skeletal myocytes expressing fskMyHC,
nd that very few donor-derived cells acquire a cardiac or
ndothelial phenotype (1,5). As expected, regions of the
eart showing fskMyHC reactivity colocalized with regions
ontaining nLacZ, a marker for the injected cells (data not
hown). Based on measurements of engraftment size in
skMyHC-stained hearts, we observed comparable engraft-
ents of MDSC-LacZ cells and MDSC-VEGF25 cells,
uggesting that VEGF overexpression in the MDSC-
EGF25 group had no effect on cell engraftment. How-
ver, VEGF overexpression adversely affected the engraft-
ent of MDSC-VEGF50 cells at the 6- and 12-week time
oints (Table 1) suggesting that long-term expression of
EGF at high concentrations in the MDSC-VEGF50
roup may have hindered donor cell engraftment at later
ime points, possibly because of VEGF toxicity or the
Figure 2 Abnormal Angiogenesis
Overexpression of VEGF in the MDSC-VEGF50–injected hearts formed disorga-
nized vasculature (CD31 immunostaining, white) 12 weeks after injection. In
contrast, we observed normal spatially organized vasculature in hearts trans-
planted with MDSCs expressing lower levels of the VEGF transgene (MDSC-
VEGF25 group) or control MDSCs (MDSC-LacZ) (200 magnification).
Abbreviations as in Figure 1.
raft Area (mm2)
Table 1 Graft Area (mm2)
2 Weeks 6 Weeks 12 Weeks
MDSC-LacZ 2.610 0.733 3.035 0.666 2.549 0.779
MDSC-FLT 3.006 0.427 2.993 0.778 2.837 0.813
MDSC-VEGF25 3.050 1.143 2.013 0.853 2.125 1.420
MDSC-VEGF50 4.002 0.305 1.465 0.574 0.889 0.195aDSC  muscle-derived stem cell; VEGF  vascular endothelial growth factor.ormation of abnormal vascular structures (Fig. 2). At all
ested time points, the MDSC-FLT cells showed fskMyHC
reas comparable to the control MDSC-LacZ cells, indicating
hat inhibition of VEGF by sFlt had no effect on cell
ngraftment.
V infarct size and scar tissue area. In cross sections of
asson’s trichrome-stained hearts, we measured LV infarct
ize (Fig. 3A) and LV scar tissue ratio (Fig. 3B). Phosphate-
uffered saline–injected hearts displayed very large LV
nfarcts and scar tissue area ratios at 2, 6, and 12 weeks after
I (Figs. 3A and 3B). In contrast, hearts in the MDSC-
acZ and MDSC-VEGF25 groups had smaller infarcts and
car-tissue areas than hearts in the PBS and MDSC-FLT
roups (p  0.05) (Figs. 3A and 3B). The MDSC-VEGF50
roup also displayed small infarcts and scar lesions at 2 and 6
eeks, but showed increased LV infarct size and scar tissue by
2 weeks (Figs. 3A and 3B). This increase in LV infarct size
Figure 3 Effect of VEGF on Infarct Scar Size
(A and B) Hearts injected with MDSC-LacZ and MDSC-VEGF25 cells displayed
smaller infarct sizes and scar tissue ratio compared with hearts injected with
PBS or MDSC-FLT cells at all time points (*p  0.05 vs. PBS; †p  0.05 vs.
MDSC-FLT). Although hearts injected with MDSC-VEGF50 cells had smaller
scars at 2 and 6 weeks, they demonstrated larger infarct sizes and scar tissue
ratio at 12 weeks (‡p  0.05 vs. MDSC-VEGF50 12 weeks; #p  0.05, 2 vs.
12 weeks). LV  left ventricle; other abbreviations as in Figure 1.nd scar tissue may again be related to the formation of
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October 23, 2007:1677–84 MDSC, VEGF, and Angiogenesis for Cardiac Repairbnormal vasculature observed in the MDSC-VEGF50-
njected hearts after 12 weeks (Fig. 2). Hearts injected with
DSC-FLT cells displayed large infarcts and scar lesions
omparable in size to levels observed in hearts injected with
BS. Thus, VEGF appears to play an integral role in MI
ound healing after MDSC transplantation.
ssessment of LV function. Representative images of
-mode echocardiography tracing for each group are
hown in Figure 4A. As assessed by EDD, progressive
nlargement of the LV cavity occurred over time in hearts in
he PBS group, indicating adverse cardiac remodeling after
I (p  0.05, 2 vs. 12 weeks) (Fig. 4B). In contrast, no
ignificant enlargement of the LV cavity occurred in the
DSC-LacZ– or MDSC-VEGF25–injected hearts over
ime (Fig. 4B). Progressive enlargement of the LV was also
bserved in the MDSC-VEGF50 hearts and the MDSC-
LT–injected hearts (p  0.05, 2 vs. 12 weeks) (Fig. 4B).
f note, these findings appear to be consistent with the
istological results in Figure 3.
Figure 4 Antagonism of VEGF Diminished the Therapeutic Effec
(A) Representative echocardiographic M-mode images of left ventricle for each gro
each image. (B) Hearts injected with PBS, MDSC-FLT cells, or MDSC-VEGF50 cells
course of the study (#p  0.05, 2 vs. 12 weeks), and these left ventricle dimensi
points (§p  0.05 vs. MDSC-LacZ and MDSC-VEGF25). In contrast, left ventricle
(C and D) Injection of MDSC-LacZ, MDSC-VEGF25, or MDSC-VEGF50 cells impr
compared with the injection of PBS and MDSC-FLT cells (*p  0.05 vs. PBS; †
VEGF50 groups decreased by 12 weeks after injection (#p  0.05, 2 vs. 12 weeks
function in the MDSC-LacZ– and MDSC-VEGF25–injected hearts was preserved. AbAs assessed by FS and FAC, hearts injected with PBS
emonstrated poor cardiac contractility 2 weeks after MI,
hich continued to decline by 12 weeks (p  0.05, 2 vs. 12
eeks). Hearts injected with MDSC-LacZ cells or MDSC-
EGF25 cells displayed better LV contractility than did
ontrol PBS-injected hearts at all time points (p  0.05)
Figs. 4C and 4D). The MDSC-VEGF50–injected hearts
lso displayed good LV systolic function at 2 and 6 weeks;
owever, 12 weeks after MI, hearts in the MDSC-VEGF50
roup displayed reduced cardiac function compared with
DSC-LacZ and MDSC-VEGF25 groups (p  0.05)
Figs. 4C and 4D). This could be due to the formation of
emangioma-like structures (Fig. 2). Hearts injected with
DSC-FLT cells displayed poor systolic function com-
ared with hearts injected with MDSC-LacZ or MDSC-
EGF25 cells at all time points (p  0.05) (Figs. 4C and
D). In comparison with the PBS-injected hearts, MDSC-
LT–injected hearts revealed no difference in FS and FAC
t any tested time points (Figs. 4C and 4D). Thus, these
MDSC Transplantation
d-systolic dimension (ESD) and end-diastolic dimension (EDD) were measured in
yed progressive enlargement of the left ventricle, as measured by EDD, over the
re larger than the MDSC-LacZ- and MDSC-VEGF25–injected hearts at all time
sions in the MDSC-LacZ– and MDSC-VEGF25–injected hearts were preserved.
eft ventricle contractility (% fractional shortening, % fractional area change)
.05 vs. MDSC-FLT). Systolic function in the PBS, MDSC-FLT, and MDSC-
0.05 MDSC-VEGF50 vs. MDSC-LacZ and MDSC-VEGF25 groups), whereas systolic
tions as in Figure 1.t of
up. En
displa
ons we
dimen
oved l
p  0
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MDSC, VEGF, and Angiogenesis for Cardiac Repair October 23, 2007:1677–84esults suggest that preservation of LV dimensions and
mprovements in cardiac function elicited after MDSC
ransplantation are related, at least partly, to the paracrine
ffects of VEGF produced in the ischemic milieu.
ecretion of VEGF by MDSCs in response to hypoxia
nd mechanical stretch. Because hypoxia is a well-known
nitiator of angiogenesis signaling (18,19), we cultured
DSCs under hypoxic conditions (2.5% O2) for 24 h, and
easured the VEGF secreted into the cell culture superna-
ant. Muscle-derived stem cells cultured in normal PM
nder hypoxic rather than normal culture conditions (20%
2) displayed a 6-fold increase in VEGF secretion (p 
.05) (Fig. 5A). Furthermore, MDSCs cultured in serum-
ree medium under hypoxic conditions secreted 9 times the
mount of VEGF expressed by MDSCs cultured in PM
Figure 5 MDSCs Secrete VEGF Under
Hypoxia and Mechanical Stimulation
(A) Compared with MDSCs cultured under normoxia (in proliferation medium
[PM]), MDSCs exposed to hypoxic conditions (2.5% oxygen) exhibited a 6-fold
increase in VEGF secretion (in PM), and a 9-fold increase if grown in serum-free
(SF) medium (*p  0.05 vs. normoxia and PM or SF). Muscle-derived stem
cells cultured under hypoxic conditions in SF-medium secreted the most VEGF.
(B) When subjected to cyclic stretch for 10 and 24 h, MDSCs increased VEGF
expression 2-fold (*p  0.05 vs. non-stretch control group). Abbreviations as
in Figure 1.mnder normal conditions (p  0.05) (Fig. 5A), indicating
hat a low-nutrient environment enhances the effect of
ypoxia on the level of VEGF secretion by MDSCs.
Because the myocardium experiences continuous cyclic
oad, we subjected MDSCs to cyclic stretch in vitro to
etermine whether mechanical forces induce a VEGF
esponse similar to that elicited by hypoxia. Ten or 24 h of
yclic stretch resulted in a 2-fold increase in VEGF secre-
ion by MDSCs (p  0.05 vs. non-stretch control) (Fig.
B). Although cyclic stretch increased secretion of VEGF
rom MDSCs, our results indicate that hypoxia is a stronger
nitiator of VEGF expression by MDSCs. The combination
f hypoxia, nutrient deprivation, and mechanical stress
likely conditions within ischemic myocardium) could in-
uce high levels of VEGF secretion by MDSCs, which
ould explain our previously reported findings that MDSCs
xpressed VEGF for up to 12 weeks after transplantation
nto infarcted myocardium (1).
iscussion
e observed that angiogenesis induced after intramyocar-
ial MDSC transplantation into infarcted hearts is depen-
ent on VEGF within the ischemic milieu. Our results
how that VEGF increases angiogenesis and is important
or the neovascularization that occurs within an MDSC-
reated MI. Inhibition of VEGF bioactivity by sFlt1 re-
ulted in decreased neoangiogenesis, increased infarct size,
nd decreased cardiac function, thus corroborating the
ngiogenic and therapeutic value of VEGF for MI repair in
DSC-treated hearts. Finally, we show that MDSCs
ecrete VEGF when stimulated by hypoxia and cyclic
tretch, implying that transplanted MDSCs are a potential
ource of the VEGF that is released into the ischemic
ilieu.
Previous studies showed that the delivery of VEGF
ransgene overexpressing myoblasts into cardiac and skeletal
uscle resulted in aberrant angiogenesis at high micro-
nvironmental dosages of VEGF (14–16). Likewise, we
bserved the formation of abnormal vascular structures in
ur highest VEGF overexpressing cell population (MDSC-
EGF50) at only the latest time point (12 weeks), suggest-
ng that we surpassed the threshold for VEGF micro-
nvironmental dosage that would lead to normal induction
f angiogenesis as demonstrated by Ozawa et al. (16).
dditionally, we observed that this was detrimental to the
ersistence of the donor cell engraftment in the MDSC-
EGF50 group (Table 1). We speculate that this abnormal
asculature and poor engraftment was detrimental to the
ealing of the infarct scar (Fig. 3) and to sustained func-
ional recovery of the LV (Fig. 4) 12 weeks after an acute
I. Such adverse events associated with abnormal vascula-
ure are consistent with a report by Lee et al. (14), who
howed that hemangiomas resulting from long-term VEGF
ransgene expression by myoblasts injected into nonische-
ic myocardium caused deleterious effects. Our results
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October 23, 2007:1677–84 MDSC, VEGF, and Angiogenesis for Cardiac Repairurther support previous findings that VEGF must be
egulated to optimize its therapeutic benefit (16).
The antagonism of VEGF with sFlt1 resulted in decreased
eovascularization, adverse remodeling, and diminished car-
iac function. This is consistent with a report by Hiasa et al.
20) demonstrating that antagonism of VEGF in hearts
njected with bone marrow-derived mononuclear cells resulted
n adverse remodeling and larger infarcts. Vascular endothelial
rowth factor may act therapeutically by reducing cardiomyo-
yte apoptosis and promoting cell proliferation and migration
arly after MI (21). The ability of the transplanted MDSCs to
elease VEGF immediately into the ischemic milieu early after
nfarction could theoretically help to salvage at-risk myocar-
ium and result in reduced infarct size, a finding that was
bserved in this study. In addition, the persistent expression of
EGF by transplanted cells for up to 12 weeks could lead to a
eduction of ischemia in the infarct through the induction of
ngiogenesis, and thereby attenuate progressively deleterious
emodeling of viable infarct and myocardial tissue (1,22).
Interestingly enough, we did not observe any significant
mprovement in cardiac remodeling or cardiac function
hen we overexpressed VEGF in comparison with our
ontrol MDSC-injected hearts. This differs from reports by
uzuki et al. (23) wherein they observed greater improve-
ents in cardiac function after transplantation of VEGF
verexpressing myoblasts when compared with control
yoblasts. A number of differences between these studies
ould account for this discrepancy in functional outcome,
ncluding the cell type (mouse MDSC vs. rat myoblast),
ethod for VEGF transgene delivery to cells (retroviral
ransduction vs. plasmid), VEGF dosage, and animal MI
odel (mouse vs. rat; cell injection immediately after
igation vs. cell injection 1 h after ligation) (1,23).
Host-derived and donor cells could both be contributing
EGF to the ischemic milieu. Host-derived cells known to
ecrete VEGF in the setting of an MI include mobilized
-kit cells from the bone marrow (24), myofibroblasts (25),
eripheral blood mononuclear cells (26), endothelial cells
ining the blood vessels (1,27), smooth muscle cells (28),
nfiltrating macrophages (28), and cardiomyocytes (28). In
ddition to the secretion of VEGF from host cells, we
uspect that engrafted donor cells release a significant
mount of VEGF to the ischemic milieu in cell-injected
earts. In our previous study, we revealed that engrafted
DSCs express VEGF within infarcted myocardium (1).
ere, we further support this by demonstrating that
DSCs secrete VEGF in response to hypoxia and cyclic
tretch, conditions likely experienced by the cells after
ransplantation into an acute MI. A similar response to
hese stresses has been documented by other cell types
11,19,29). Collectively, these findings suggest that the
schemic milieu of a myocardial infarct is an important
rigger for VEGF production by engrafted cells, and that
ransplanted cells are a significant source of VEGF within
he ischemic myocardium. However, because sFlt1 secreted
rom donor MDSCs in this study could theoretically blockndogenous (host cell-expressed) and exogenous (donor
ell-expressed) VEGF, we could not precisely determine
hether the VEGF secreted directly from the engrafted
ells was solely or partially responsible for the angiogenic
nd therapeutic effects elicited after cell injection into an
I. Future experiments designed to specifically inhibit
onor cell expression of VEGF will be performed to address
his issue.
onclusions
his study highlights the angiogenic and therapeutic value of
EGF in the setting of an acute MI treated by an intramyo-
ardial transplantation of MDSCs. The findings of this study
ignify an important relationship between VEGF, angiogene-
is, and functional recovery for cardiac cell therapy.
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